145 related articles for article (PubMed ID: 7480563)
1. Stress and the erectile response to intracavernosal prostaglandin E1 in men with erectile dysfunction.
Granata A; Bancroft J; Del Rio G
Psychosom Med; 1995; 57(4):336-44. PubMed ID: 7480563
[TBL] [Abstract][Full Text] [Related]
2. The clinical assessment of erectile dysfunction: a comparison of nocturnal penile tumescence monitoring and intracavernosal injections.
Bancroft J; Malone N
Int J Impot Res; 1995 Jun; 7(2):123-30. PubMed ID: 7496441
[TBL] [Abstract][Full Text] [Related]
3. Effect of Intracavernosal Injection of Prostaglandin E1 on Duration and Rigidity of Erection in Patients With Vasculogenic Erectile Dysfunction: Is It Dose Dependent?
Bassiem MA; Ismail IY; Salem TA; El-Sakka AI
Urology; 2021 Feb; 148():173-178. PubMed ID: 33017615
[TBL] [Abstract][Full Text] [Related]
4. Erectile response to visual erotic stimuli before and after intracavernosal papaverine, and its relationship to nocturnal penile tumescence and psychometric assessment.
Bancroft J; Smith G; Munoz M; Ronald P
Br J Urol; 1991 Dec; 68(6):629-38. PubMed ID: 1773296
[TBL] [Abstract][Full Text] [Related]
5. What does duplex ultrasound add to sexual history, nocturnal penile tumescence and intracavernosal injection of smooth muscle relaxant, in the diagnosis of erectile dysfunction?
Gutierrez P; Pye S; Bancroft J
Int J Impot Res; 1993 Sep; 5(3):123-31; discussion 132. PubMed ID: 8124430
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of erectile responses to vasoactive drugs by a variable amplitude oscillation device.
Chun SS; Fenemore J; Heaton JP; Johnston B; Morales A
Int J Impot Res; 1996 Dec; 8(4):221-5. PubMed ID: 8981171
[TBL] [Abstract][Full Text] [Related]
7. An attempt to standardize the pharmacological diagnostic screening of vasculogenic impotence with prostaglandin E1.
McMahon CG
Int J Impot Res; 1995 Jun; 7(2):83-90. PubMed ID: 7496445
[TBL] [Abstract][Full Text] [Related]
8. Failure to attain stretched penile length after intracavernosal injection of a vasodilator agent is predictive of veno-occlusive dysfunction on penile duplex Doppler ultrasonography.
Yafi FA; Libby RP; McCaslin IR; Sangkum P; Sikka SC; Hellstrom WJ
Andrology; 2015 Sep; 3(5):919-23. PubMed ID: 26235901
[TBL] [Abstract][Full Text] [Related]
9. Comparison of intraurethral liposomal and intracavernosal prostaglandin-E1 in the management of erectile dysfunction.
Engelhardt PF; Plas E; Hübner WA; Pflüger H
Br J Urol; 1998 Mar; 81(3):441-4. PubMed ID: 9523667
[TBL] [Abstract][Full Text] [Related]
10. Relation between intracavernosal dose of prostaglandin Pge 1 and mean duration of erection in men with different underlying causes of erectile dysfunction.
Bratus D; Hlebic G; Hajdinjak T
Croat Med J; 2007 Feb; 48(1):76-80. PubMed ID: 17309142
[TBL] [Abstract][Full Text] [Related]
11. Determinants of satisfactory rigidity after intracavernosal injection with prostaglandin E1 in men with erectile failure.
Purvis K; Brekke I; Christiansen E
Int J Impot Res; 1996 Mar; 8(1):9-16. PubMed ID: 8735188
[TBL] [Abstract][Full Text] [Related]
12. Anxiety and high plasma catecholamines do not impair pharmaco-induced erection of psychogenic erectile dysfunctional patients.
Pagani E; Glina S; Puech-Leão P; Strunz CM; Chao S; Timo-Iaria C
Int J Impot Res; 2003 Aug; 15(4):282-6. PubMed ID: 12934057
[TBL] [Abstract][Full Text] [Related]
13. Injection anxiety and pain in men using intracavernosal injection therapy after radical pelvic surgery.
Nelson CJ; Hsiao W; Balk E; Narus J; Tal R; Bennett NE; Mulhall JP
J Sex Med; 2013 Oct; 10(10):2559-65. PubMed ID: 23898886
[TBL] [Abstract][Full Text] [Related]
14. Anxiety-induced failure in erectile response to intracorporeal prostaglandin-E1 in non-organic male impotence: a new diagnostic approach.
Aversa A; Rocchietti-March M; Caprio M; Giannini D; Isidori A; Fabbri A
Int J Androl; 1996 Oct; 19(5):307-13. PubMed ID: 8985780
[TBL] [Abstract][Full Text] [Related]
15. Why a combined intracavernosal injection with trimix and oral sildenafil is reliable therapy in the ultrasonographic evaluation of erectile dysfunction.
Park JK; Park JS; Jeon SB; Cui WS; Kim SZ; Kang KK; Lee SW
BJU Int; 2008 Sep; 102(8):993-7. PubMed ID: 18476965
[TBL] [Abstract][Full Text] [Related]
16. [Prostaglandin E1 in the diagnosis and therapy of erectile disorders].
Loran OB; Segal AS; Shcheplev PA
Urol Nefrol (Mosk); 1995; (4):35-8. PubMed ID: 7571200
[TBL] [Abstract][Full Text] [Related]
17. Vascular interventions for impotence: lessons learned.
DePalma RG; Olding M; Yu GW; Schwab FJ; Druy EM; Miller HC; Massarin E
J Vasc Surg; 1995 Apr; 21(4):576-84; discussion 584-5. PubMed ID: 7707563
[TBL] [Abstract][Full Text] [Related]
18. Nocturnal penile tumescence activity unchanged after long-term intracavernous injection therapy.
Maniam P; Seftel AD; Corty EW; Rutchik SD; Hampel N; Althof SE
J Urol; 2001 Mar; 165(3):830-2; discussion 832-3. PubMed ID: 11176480
[TBL] [Abstract][Full Text] [Related]
19. Clinical and duplex US assessment of effects of sildenafil on cavernosal arteries of the penis: comparison with intracavernosal injection of vasoactive agents--initial experience.
Copel L; Katz R; Blachar A; Sosna J; Sheiman RG
Radiology; 2005 Dec; 237(3):986-91. PubMed ID: 16237136
[TBL] [Abstract][Full Text] [Related]
20. Intracavernous injection of prostaglandin E1 for the treatment of erectile impotence.
Ishii N; Watanabe H; Irisawa C; Kikuchi Y; Kubota Y; Kawamura S; Suzuki K; Chiba R; Tokiwa M; Shirai M
J Urol; 1989 Feb; 141(2):323-5. PubMed ID: 2913354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
